er dette noe å henge med hue for da:
Fondsfinans har tatt ut en liten gevinst/potefølje justering
HH sitter så klart da han ser at han gjerne kan få 4 x mer for aksjene sine allerede tidlig neste år.
Og Hestdal trengte bare litt lommepenger til ferieturen. 
Tydeligvis ikke mye interesse for PHO her på Tekinvestor. Pussig egentlig, for man skal ikke være så voldsomt godt møbelert i toppetasjen for å skjønne at vi her har å gjøre med et selskap som markedet kraftig undervurderer. Det skyldes trolig selskapets begredelig forhistorie. Mange har nok trolig vært innom PHO tidligere år og har måttet selge seg ut igjen med tap og blitt dissillusjonert.
Men jeg tror nok at man kan gjøre smart i å sette seg inn i hva som har skjedd etter Fase III studien var ferdig. Selskapet står nå midt i et taktskifte og et gjennombrudd i det amerikanske markedet. Sannsynligheten for suksess her er stigende dag for dag ettersom etterspørselen etter BLC er stigende. Den endelige bekreftelsen får vi trolig på Q3 presentasjonen, etter at vi fikk en teaser på Q2. Men en teaser som så veldig mye.
I dag ser det ut som om kursen bryter opp gjennom motstanden på kr 45,-.
1 Like
Det kunne absolutt vært litt bedre interesse rundt PHO her ja.
De fleste sjekker vel HO også vil jeg tro.
Jeg skulle i etterpåklokskapens lys gjerne hatt snudd portefølgen min fra 90/10 i favør PCIB til favør PHO den siste perioden, men det er ikke lett å se hvordan det vil utvikle seg og når Hunter Hall fortsatt vil ut så er det vel de som holder igjen utviklingen.
Jeg kjøpte litt mer i går gjennom DNB og den ble ikke med i loggen, så den ble nok omsatt i DNB darkpool.
Idag derimot ble den synlig i loggen.
1 Like
etter å ha vært all-in i NANO har jeg flyttet mer og mer over til PHO siste månedene. har vært god butikk det, selv om jeg har troen på NANO på sikt. For pho så kommer man til dekket bord
1 Like
Er ikke så mye å si, vi venter på salg og rapporter fra selskapet.
Hold på aksjene er vel det eneste en kan si.
2 Likes
da økte vi litt til idag gitt
Photocure ASA: Exclusive Nordic distribution agreement for innovative drug delivery system for bladder cancer patients
Oslo, Norway, August 27, 2018 : Photocure ASA, The Bladder Cancer Company, announces today that an exclusive distribution agreement for the Nordic area for an innovative and patented medical device has been signed with Combat Medical (www.combat-medical.com). The device is designed for the delivery of Hyperthermic Intra-Vesical Chemotherapy (HIVEC) for non-muscle invasive bladder cancer and has a strong strategic and synergistic fit with current business.
“The distribution agreement with Combat Medical is a milestone for Photocure as it represents the first step in expanding our portfolio and our footprint in the bladder cancer field. We are proud to be a recognized player in the field and chosen as a partner for an innovative drug delivery device. It is also a significant step towards our vision: Driving Change in Bladder Cancer Management. The delivery system represents an excellent strategic fit to our expertise and current Blue Light Cystoscopy with Hexvix business. More than 7000 patients are diagnosed with non-muscle invasive bladder cancer in the Nordic area every year, and approximately 50% of them will undergo repeat instillation therapy,” says Erik Dahl, CFO and Interim CEO of Photocure.
Hyperthermia has been shown to significantly increase the effectiveness of chemotherapy. HIVEC using the Combat BRS has the potential to become an attractive alternative to other instillation treatments for medium- and high-risk patients. Clinical hyperthermia is defined as the therapeutic use of temperature between 41°C to 44°C. At 43°C the cytotoxicity increases by 10 times, without any increase in the toxicity to the patient. The highly automated medical device system is conveniently integrated in the out-patient clinic.
“We are delighted to have Photocure as our partner in the Nordic area. In addition to their bladder cancer expertise they also have a proven track record in introducing new technologies, requiring both disease and clinical expertise, as well as competence in maneuvering the complex hospital organizations and facilitating training of the urologists and nurses in the use of new devices. We very much look forward to collaborating with Photocure and sharing our expertise and experiences from the countries where our delivery system is already in routine use,” says Edward Bruce-White, CEO of Combat Medical.
The patented hyperthermic delivery solution consists of a recirculation unit ensuring effective temperature control and specifically designed disposable catheter. An extensive clinical program to further document safety and effectiveness is underway. Photocure is Combat Medical’s exclusive commercialization partner for the Nordic area and will use the existing specialist team, target exactly the same health care providers, hospitals and patients as with Hexvix.
“We are proud to be the first hospital in the Nordic area who got the chance to use this promising technology to treat our patients. We are currently generating and collecting data and assessing the convenience of introducing the technology into our facility. The procedure is highly automated and can easily be performed by trained nurses. We look forward to collaborating with Photocure on this new technology which could potentially become a new tool for better management of bladder cancer patients, just like Hexvix has proven to be over the last 10 years”, says Professor Jørgen Bjerggaard Jensen, Aarhus University Hospital, Denmark.
Photocure will leverage on the extensive Hexvix infrastructure in the Nordics for implementation of the Combat Medical distribution agreement and expects commercial sales to commence from the first quarter of 2019.
About the Combat BRS and HIVEC treatment
The Combat BRS delivers HIVEC to optimize the chemotherapy installation for non-muscle invasive bladder cancer patients. Maximizing the efficacy of the treatment by harnessing the proven combined effects of chemotherapy and hyperthermiaThe patented, technically innovative device has been in clinical use since 2011. Safety, tolerability and efficacy data from over 500 patients have already been presented as part of the ongoing extensive clinical programme.
The System is easy to integrate into clinical practice, it requires minimal additional resources for the healthcare provider whilst maximising outcomes for patients with this type of bladder cancer.
References
G Schooneveldt, A Bakker, E Balidemaj, R Chopra, J, Crezee, ED Geijsen,J, Hartmann, MC Hulshof, HP Kok, MM paulides, A Sousa -Escandon, PR Stauffer, PR Maccarini. Thermal dosimetry for bladder hyperthermia treatment. An overview. International journal of Hyperthermia. 2016 Jun;32 (4):417-33
Dahl, O., Dalene, R., Schem, B. C. & Mella, O. Status of clinical hyperthermia. Acta Oncol. 38, 863-73 (1999)
Teicher, B. A., Kowal, C. D., Kennedy, K. A. & Sartorelli, A. C. Enhancement by Hyperthermia of the in Vitro Cytotoxicity of Mitomycin C toward Hypoxic Tumor Cells. Cancer Res. 41, 1096-1099 (1981).
Plata BA, Garcia AC,Villacampa F,GonzalezD, Llanes L, Diaz Goizueta J, Rios E,RimingtonP, castillo JM, Castillo DJ,Pontones JL,Nzeh C, Brisuda , Leon J, Sousa A, Chiancone F, Fedelini P,Hendricksen K, Vögeli TA, Frank, E, Wilby D, Chemohyperthermia with Mitomycin C and COMBAT System, A new alternative to BCG in High Risk Non Muscle Invasive Bladder Cancer. The Journal of Urology, Vol 199, issue 4, e1119, April 2018
5. WS Tan, J palou, J Kelly, safety & Tolerability analysis of hyperthermic intravesical mitomycin to mitomycin alone in HIVEc I and II: an interim analyiss of 307 patients.
6. A Sousa, I Pineiro, S Rodroguez, V Aparici, V Monserrat, P Neira, E carro, C Murias, C Uribarri. Recirculant Hyperthermic IntraVesical chemotherapy (HIVEC) in intermediate-high risk non muscle invasive bladder cancer, International Journal of Hyperthermia, 2016 Vol32,No4,374-380
About Bladder Cancer in the Nordic area
There are more than 7 000 new cases of bladder cancer in the Nordic and more than 2 000 deaths from the disease annually. Approx. 75% of all bladder cancer cases occur in men. It has a high recurrence rate with an average of 61% in year one and 78% over five years. Bladder cancer has the highest lifetime treatment costs per patient of all cancers.
Bladder cancer is a costly, potentially progressive disease for which patients have to undergo multiple cystoscopies due to the high risk of recurrence. There is an urgent need to improve both the diagnosis and the management of bladder cancer for the benefit of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of invasion in the bladder wall. NMIBC remains in the inner layer of cells lining the bladder. These cancers are the most common (75%) of all BC cases and include the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. MIBC is when the cancer has grown into deeper layers of the bladder wall. These cancers, including subtypes T2, T3 and T4, are more likely to spread and are harder to treat.
- Globocan. Incidence/mortality by population. Available at: http://globocan.iarc.fr/Default.aspx
- Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al. EAU Guidelines on non- muscle-invasive bladder cancer (Ta, T1 and CIS). Eur Urol. 2016 Guidelines Edition:1-40.
- Sievert KD et al. World J Urol 2009;27:295-300
- Bladder Cancer. American Cancer Society. https://www.cancer.org/cancer/bladder-cancer.html
About Combat Medical
Combat Medical is an innovative specialist hyperthermic medical device company which is leading the way in the development of hyperthermic cancer treatments, together with a multidisciplinary team of experts. Combat’s systems for the treatment of cancer of the bladder, peritoneum, ovaries and abdominal organs are currently used in more than 250 centres in over 35 countries worldwide.For more information please visit us at https://hivec.co.uk/company/
About Photocure ASA
Photocure, The Bladder Cancer Company, delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.comCompany contacts:
For Photocure:
Erik Dahl, Chief Financial Officer and Interim CEO
Tel: +47 450 55 000
Email: ed@photocure.noFor Combat Medical:
Edward Bruce-White, CEO and Co-Founder
Tel: +44 1582 834 466
Email: ebw@combat-medical.comTrademarks
All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA or Combat Medical ltd.Disclaimer
This press release may contain product details and information which are not valid, or a product is not accessible, in your country. Please be aware that Photocure or Combat Medical ltd does not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Photocure ASA via GlobenewswireNyheten er levert av GlobeNewswire.
http://www.netfonds.no/quotes/release.php?id=20180827.GlobeNewswire.HUG2212744
Noen som så denne komme?
Startes spekulasjoner på at dette selskapet kan være en mulig fusjonspartner?
En hyggelig overraskelse!
Topp 50 viser desverre hvorfor prisen flater ut. Gevinstsikring fra de største aksjonærene, bortsett fra High seas
Får satse på at nye langsiktige interesser posisjonerer seg utover høsten.
Spent på å få mer info rundt dette. Er utstyret godkjent i USA og når kommer det eventuelt inn på det amerikanske markedet? Hva er inntjeningspotensialet for utstyret?
Det utløser en mengde spørsmål, men samtidig viser det at PHO er fremoverlent og mener alvor. Men utstyret sies å ha vært i bruk siden 2011, så her må det da være investorer som har kjennskap til dette fra tidligere?
Distribusjonsavtale i Norden betyr vel neppe allverden. Målet for PHO er trolig at de ved å ha inngått en distribusjonsavtale i Norden skal ha gode muligheter å oppnå det samme for det amerikanske markedet. For utstyret er såvidt jeg kan finne ut ennå ikke tilgjengelig i USA. Men ettersom BLC nå er i ferd med å få en akselererende vekst i USA, så ser jeg ikke bort fra at denne utviklingen kan bli som en spydspiss for å få introdusert HIVEC til de samme klinikkene. Uvisst hvor mye PHO kan tjene på dette. Blir spennende å se.
Hivec/Hipec er en metode for «skylle» vev med en mix av varmt vann og cellegift.
Brukes i bukhulen ved spredning dit.
Brukes sikkert andre steder også.
Pasientene gjennomgår en ganske omfattende operasjon hvor tarmene ligger på en benk eller noe I mellomtiden. Også skylles vevet med løsningen.
Dette gjør at cellegiften treffer mer lokalt enn intravenøs spredning.
Dette er brukt i norge i noen år allerede. Men antallet som får behandlingen er begrenset og eldre bortprioriteres.
Det har vært mulig å få behandlingen privat bla i sverige.
Produktet til Oncoinvent, ved lik effekt vil antagelig bli bedre for passientene ved behandling av bukhulemetastaser. (Pga ikke/mindre operasjon og mindre dose for «lik effekt»)
Men veit ellers ikke mer om bruksområder/forskjeller på disse to produktene. Feks ang bruken mot blære.
1 Like
Hivec (intravescial betyr i blæra)
Hipec (intraperitoneal, betyr i bukhulen)
Så metoden er kanskje lik, bare forskjellig område
ja, men der er noen som klatrer tilsvarende så ser ikke helt svart på det.
De store her som sikrer trenger nok litt cash til andre aksjer.
Men eg sier bare eg som sagt før : hold på aksjene:)
Feil tråd, sorry
1 Like
pcib snøffel , no er du på pho;)
feil tråd
Oops, beklager skal rette opp i den…
1 Like
Og der var vi oppe og nappet litt i 50-tallet for første gang på halvannet år